blood test to detect the presence or absence of cancer

Not Applicable

Completed

• Conditions: Health Condition 1: C00-D49- Neoplasms

• Registration Number: CTRI/2019/01/017166
• Lead Sponsor: Epigeneres Biotech Pvt Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-05-31
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 1000

Inclusion Criteria

Have any type of histologically or cytologically

proven (solid tumors or haematological ) cancer

which will assist in meeting the Primary

objective of this study (Cancer group)

(OR)

ï?· Individuals who are NOT a known case of any

malignancy( Non-Cancer group)

ï?· Are aged 18 years or older.

ï?· Are willing to consent to storage of specimens for

future research.

ï?· Are willing to comply with study procedures and

follow-ups

ï?· Subjects enrolled will be able to provide

informed consent for themselves.

Exclusion Criteria

Are incarcerated.

ï?· Are unwilling or unable to comply with

prescribed therapy.

ï?· Subjects that lack the capacity to provide

informed consent autonomously are to be

excluded.

ï?· Pregnant or lactating women.

ï?· Subjects who have participated in any clinical

trial in the past 1 month.

ï?· Any subjects found to have entered into the study

in violation of this protocol or if the subject is

uncooperative during the study

ï?· Any other condition that in the opinion of the

investigator that does not justify the subjectâ??s

participation in the trial.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The expression profile of the molecular immuno- <br/ ><br>markers will help in analysing the probability of manifestation of cancer, before any clinical <br/ ><br>symptoms begin to appear in healthy individuals. <br/ ><br> <br/ ><br>The expression profile of the molecular immuno-markers in cancer patients will help in determining the efficacy of the ongoing <br/ ><br>treatment and for cancer survivors it will aid in determining the risk of relapse of the disease.Timepoint: 30 days

Secondary Outcome Measures

Name	Time	Method
To follow up with pre-cancer/ high-risk individuals and selected cancer individuals with <br/ ><br>telephonic visits every 3 months and conduct blood test at every six monthsTimepoint: five years